0000899243-23-019711.txt : 20231003
0000899243-23-019711.hdr.sgml : 20231003
20231003143031
ACCESSION NUMBER: 0000899243-23-019711
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231002
FILED AS OF DATE: 20231003
DATE AS OF CHANGE: 20231003
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KHANDROS IGOR Y
CENTRAL INDEX KEY: 0001256946
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39388
FILM NUMBER: 231302748
MAIL ADDRESS:
STREET 1: 25 HACIENDAS ROAD
CITY: ORINDA
STATE: CA
ZIP: 94563
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Bruker Cellular Analysis, Inc.
CENTRAL INDEX KEY: 0001689657
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 352415390
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5858 HORTON STREET
STREET 2: SUITE 320
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
BUSINESS PHONE: 510-858-2855
MAIL ADDRESS:
STREET 1: 5858 HORTON STREET
STREET 2: SUITE 320
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
FORMER COMPANY:
FORMER CONFORMED NAME: PhenomeX Inc.
DATE OF NAME CHANGE: 20230320
FORMER COMPANY:
FORMER CONFORMED NAME: Berkeley Lights, Inc.
DATE OF NAME CHANGE: 20161109
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-10-02
0
0001689657
Bruker Cellular Analysis, Inc.
CELL
0001256946
KHANDROS IGOR Y
C/O BRUKER CELLULAR ANALYSIS, INC.
5858 HORTON STREET, SUITE 320
EMERYVILLE
CA
94608
1
0
0
0
0
Common Stock
2023-10-02
4
M
0
70000
D
8819993
D
Common Stock
2023-10-02
4
D
0
8819993
D
0
D
On October 2, 2023, pursuant to the Agreement and Plan of Merger dated as of August 17, 2023 (the "Merger Agreement"), by and among Bruker Corporation ("Bruker"), Bird Mergersub Corporation ("Merger Sub") and Phenomex Inc. (the "Company"), Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Bruker (the "Merger"), and each restricted stock unit ("RSU") held by the Reporting Person was cancelled and converted into the right to receive $1.00 per share in cash (the "Merger Consideration").
Pursuant to the Merger, the Reporting Person disposed of each RSU held by him in exchange for the Merger Consideration.
8,819,993 shares of common stock directly held by family trusts of which Dr. Khandros is a trustee.
Pursuant to the Merger Agreement, each outstanding share of Common Stock, par value $0.00005 per share ("Common Stock") held by the Reporting Person was cancelled and converted into the right to receive the "Merger Consideration.
Pursuant to the Merger, the Reporting Person disposed of all shares of Common Stock beneficially owned by him in exchange for the Merger Consideration.
/s/ Christine Nassi, Attorney-in-fact for Igor Y. Khandros
2023-10-03